Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.
Author: The Medical News
SARcode’s SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting
SARcode Corporation announced today that clinical data for their lead compound, SAR 1118, has been accepted for presentation during the upcoming Association for Research in Vision and Ophthalmology Annual Meeting being held May 1–May 5, 2011, in Fort…
Positive data from Omeros’ OMS302 Phase 2b trial in patients undergoing cataract surgery
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial…
SMR, RTU enter license agreement for RESCULA eye drops
Sucampo Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Sucampo Manufacturing & Research AG, and R-Tech Ueno, Ltd., a pharmaceutical company founded in Japan in 1989, have entered into a license agreement for RESCULA eye drops, …
Retina Implant to join with Wills Eye for U.S. artificial vision clinical trial
Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced that they will partner with the Wills Eye Institute in Philadelphia as the lead U.S. clinical trial investigator site.
Eating fish protects from blindness: Study
According to latest study fish that is rich in omega 3 fatty acids significantly lowers the risk of developing age-related macular degeneration that leads to blindness. The study was published in the Archives of Ophthalmology.
How brain processes facial identity
It is no surprise to scientists that the largest social network on the web is called Facebook. Identifying people by their face is fundamental to our social interactions, one of the primary reasons vision researchers are trying to find out how our brai…
FDA approves Rochester Nomogram technology for LASIK surgery
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Eating fatty fish reduces blindness risk from AMD: Study
New research has shown that consuming omega-3 fatty acids that are most commonly found in oily fish such as tinned salmon and tuna, could prevent the onset of age-related macular degeneration (AMD), a condition that leads to the gradual loss of vision….
New self-monitoring blood glucose sensor uses tear fluid as sample
People with diabetes could be helped by a new type of self-monitoring blood glucose sensor being developed by Arizona State University engineers and clinicians at Mayo Clinic in Arizona.
Omeros fourth quarter net loss increases to $7.2 million
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter an…
ExonHit Therapeutics consolidated revenues increase 67% to € 8.2 million
The Supervisory Board of ExonHit Therapeutics met on March 14 to close the consolidated financial results for the year ending December 31, 2010. These accounts were audited by the auditors.
European Patent Office grants ProtAffin key patent for CellJammer discovery technology
ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery tech…
Genentech announces positive outcomes from Lucentis Phase III trial against DME
Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who r…
FDA accepts Merck’s SAFLUTAN NDA for standard review
Merck, known as MSD outside the United States and Canada, announced today that the New Drug Application for SAFLUTAN, Merck’s investigational preservative-free prostaglandin analogue ophthalmic solution, has been accepted for standard review by the U.S…
Aerie Pharmaceuticals closes $30 million Series B financing
Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $30 million Series B financing.
Springtime may cause or worsen dry eye condition
Springtime may be just what the doctor orders for individuals suffering from dry eye condition, a disorder resulting from insufficient tear production or altered tear film composition. According to a study published in Investigative Ophthalmology & Vis…
Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on …
NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses
The National Eye Institute and Food and Drug Administration are sponsoring a conference to determine how functional vision-related endpoints for clinical trials of visual prostheses will be analyzed and correlated with objective measures of visual acui…
International conference to address pediatric congenital cataract treatment in New York City
An international conference addressing the treatment of children born with a cataract will take place in New York City on Friday, March 11, 2011.